TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Cell-Free DNA and RNA in Blood fromMetastatic Prostate Cancer Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* A diagnosis of histologically confirmed prostate adenocarcinoma and falling into one of the following 5 groups:~  * Currently receiving ADT (previously untreated for metastatic disease)~    * These patients will be grouped into 3 cohorts: having received ADT for 3-6 months; for 1-2 years; and for \> 3 years~ * Scheduled to begin treatment with ADT (previously untreated for metastatic disease)~ * Scheduled to begin treatment with enzalutamide (castration resistant / has received ADT / may have received abiraterone)~ * Scheduled to begin treatment with abiraterone (castration resistant / has received ADT / may have received enzalutamide)~ * Scheduled to begin treatment with docetaxel (castration resistant / has received ADT / has received enzalutamide and/or abiraterone)~* Have been diagnosed with either hormone-naive or castrate-resistant metastatic disease~* Ability and willingness to provide written and informed consent~Exclusion Criteria:~* Patients who receive combined ADT with docetaxel for hormone-naive metastatic prostate cancer~* Patients on intermittent ADT

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ancillary-Correlative (blood collection) (Type: None): Patients undergo blood collection every 4-12 weeks during ADT, abiraterone, enzalutamide, or docetaxel treatment. Patients switched from ADT to either abiraterone or enzalutamide during the study will undergo phlebotomy every 6-12 weeks. Samples are analyzed for cfRNA, and cfDNA, AR-V7, and other AR-Vs via quantitative RT-PCR.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Reduced Radiation Dose and IR-impact on Coronary Calcium Quantification

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing routine calcium scoring CT at facilities at the University of Pennsylvania~Exclusion Criteria:~* Patients found to have no coronary calcium on full dose FBP reconstructions

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Tozadenant

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~All subjects must fulfill the following to participate:~* Subject has given his/her written informed consent on an IEC or IRB approved consent form.~* Subject understands the study procedures in the informed consent form (ICF), and is willing and able to comply with the protocol.~* Be either male or female 18 years old~* Have a BMI ≥ 18.5 and ≤ 40.0 kg/m2 at screening~* Is a continuous non-smoker or a smoker who will consume up to 10 cigarettes/day~* Child bearing females should be sexually inactive (abstinent) prior to dosing~* Females subjects of non childbearing potential must have undergone one of the following sterilization or be postmenopausal~Subjects with mild, moderate, or severe hepatic impairment must:~* Have a medical history consistent with a diagnosis of hepatic impairment.~* Have a diagnosis of chronic (\> 6 months), stable hepatic insufficiency~Healthy subjects must be:~* Medically healthy with no significant medical history~Exclusion Criteria:~Subjects must not be enrolled in the study if they:~* Previously participated in any study with tozadenant~* Has orthostatic hypotension, history or symptoms of cardiovascular disease, or hypertensive crisis.~* Currently participating in or has participated in another study and received drug (active or placebo)~* Have a known diagnosis of malignant melanoma~* Have a current episode of major depression~* Has a recent history of suicide attempt~* Has any other condition or clinically significant abnormal findings on the physical or neurological examination, psychiatric and medical history~* Had surgery or any medical condition within 6 months~* Unable to refrain from or anticipates the use of any drugs, vitamins, natural or herbal supplements~* Subject is currently lactating or pregnant or planning to become pregnant.~* Recent donation of blood, plasma or significant blood loss~* Has positive test for ethanol or drugs of abuse or a history of chronic alcohol or drug abuse~* Clinically significant medical history~* Positive results hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) for Healthy Volunteers only.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Healthy Subjects (Type: ACTIVE_COMPARATOR): Study dose of 120 mg
- Mild Hepatic Impairment (Type: EXPERIMENTAL): Study dose of 120 mg
- Moderate Hepatic Impairment (Type: EXPERIMENTAL): Study dose of 120 mg
- Severe Hepatic Impairment (Type: EXPERIMENTAL): Up to a maximum study dose of 120 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Energy Consumption and Cardiorespiratory Load During Overground Gait Training With a Wearable Exoskeleton After Stroke

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Included will be persons who~* Had a stroke~* Cannot walk independently or can walk independently on level ground, but still require help on stairs, slopes or uneven surfaces (FAC 0 - 4)~Excluded will be persons who~* Can walk independently on level ground, stairs, slopes and uneven surfaces (FAC 5)~* Have musculoskeletal problems (other than stroke) affecting the ability to walk~* Have concurrent pulmonary diseases (e.g. asthma)~* Have unstable cardiovascular conditions~* Have concurrent neurological diseases (e.g. Parkinson's Disease)~* Have communicative and/or cognitive problems affecting the ability to understand or follow instructions~* Present contra-indications for using the Ekso GT (according to manufacturer's instructions)~  * Severe concurrent medical diseases (infections, circulatory, heart or lung, pressure sores)~ * Severe spasticity (Ashworth 4)~ * Range of motion restrictions that would prevent a patient from achieving normal, reciprocal gait pattern, or would restrict a patient from completing normal sit-to-stand or stand-to-sit transitions~    * Bilateral hip flexion \< 110°~   * Knee flexion contracture \> 12°~   * Inability to achieve 0° neutral angle dorsiflexion with knee flexion ≤ 12°~ * Weight ≥ 100 kg~ * Hip width \< 35.8 cm or \> 45.6 cm~ * Upper leg length \< 51 cm or \> 61.4 cm~ * Lower leg length \< 48 cm or \> 63.4 cm~ * Upper leg length discrepancy \> 0.5 inch (1.3 cm)~ * Lower leg length discrepancy \> 0.75 inch (1.9 cm)~ * Unstable spine, unhealed limbs or pelvic fractures~ * Unhealthy bone density~ * Heterotopic ossification~ * Significant contractures~ * Elbows and shoulders are unable to support crutches, walker or cane~ * Psychiatric or cognitive situations that may interfere with proper operation of the device

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ekso GT gait training (Type: EXPERIMENTAL): Participants will be measured during three Ekso GT gait trainings:~* 20-minute Ekso GT gait training with high swing assistance~* 20-minute Ekso GT gait training with neutral swing assistance~* 20-minute Ekso GT gait training with high swing resistance.~Each training will be performed on a separate day in a randomized order (within one week and controlled for time of day).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating 2 Dosing Regimens Of TRU-015 In Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of active seropositive rheumatoid arthritis on a stable dose of methotrexate (7.5-25 mg weekly) for at least 12 weeks with or without a history of anti-TNF use.~Exclusion Criteria:~* Any prior use of rituximab or other B cell depleting agents.~* Any significant health problem other than rheumatoid arthritis~* Clinically significant laboratory abnormalities

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Consists of Arms 1a and 1b
- Arm 2 (Type: EXPERIMENTAL): Consists of Arms 2a and 2b
- Arm 3 (Type: PLACEBO_COMPARATOR): Consists of Arms 3a and 3b.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Real Time Amplitude Spectrum Area to Guide Defibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~All adult patients (age ≥ 18) suffering of out-of-hospital non traumatic cardiac arrest of presumably cardiac etiology with a presenting shockable rhythm requiring electrical defibrillation: Ventricular Fibrillation and pulseless Ventricular Tachycardia.~Exclusion Criteria:~* age \< 18 years old~* pregnancy~* cardiac arrest with a non-shockable rhythm (pulseless electrical activity and asystole)~* a defibrillation delivered by an AED prior to ALS arrival~* cardiac arrest of traumatic origin~* non-cardiac cause of cardiac arrest~* presumable irreversible death or known terminal illness at the beginning of ALS~* clinical death~* participation in another clinical or device trial within the previous 30 days~* refused informed consent to the use of data.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AMSA-CPR (Type: EXPERIMENTAL): The professional rescuer decides to deliver the defibrillation attempt based on the AMSA value displayed in the defibrillator
- Standard-CPR (Type: ACTIVE_COMPARATOR): The defibrillation is delivered based on the 2015 European Resuscitation Council CPR guidelines

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Chest CT With Iterative Reconstruction as an Alternative to Conventional Chest X-ray Prior to Heart Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years old or older~* Scheduled to undergo heart surgery~* Provide written informed consent~Exclusion Criteria:~* Patient not meeting inclusion criteria~* Pregnant women~* Scheduled to undergo transcatheter aortic valve insertion procedure (since these patients receive a standard preoperative CT)~* Chest or cardiac CT in the past three months~* Emergency surgery~* Concomitant or previous participation in a study that prohibits the patient from participating in a study that exposed the patient to radiation~* Unwillingness to be informed about unrequested findings on the CT scan

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): Routine clinical care (which includes a conventional chest X-ray).
- CT scan (Type: EXPERIMENTAL): Routine clinical care, which includes a chest x-ray, with an additional ultra low-dose non contrast enhanced chest CT with IR (performed preoperatively).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Follow-up Study of Autologous Adipose-derived Stem Cells (ANTG-ASC) for the Complex Fistula (ANTG-ASC-211)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* the patients who have participated in ANTG-ASC-210 clinical trial~* the patients with complete closure at week 8 after last injection in ANTG-ASC-210 trials~* the patients who submit written informed consents and is able to obey requirements of trials~Exclusion Criteria:~* a patient who has a history of variant Creutzfeldt Jacobs disease or related diseases~* a patient who is allergic to anesthetics, bovine derived proteins or a fibrin glue~* a patient who has an autoimmune disease~* a patient who has infectious diseases such as hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV)~* a patient who has a symptom of septicemia or active tuberculosis (contain tuberculosis of anus and rectum)~* a patient who is pregnant or breast feeding~* a patient who is not willing to use effective contraceptive methods during the study~* a patient who has inflammatory Bowel disease~* a patient who is sensitive to fibrin glue~* a patient who have a clinically relevant history of abuse of alcohol or drugs, habitual smoker (who smoked more than 20 cigarettes a day)~* a patient who is not able to understand the objective of this study or to comply with the study requirements~* a patient who is considered to have a significant disease which can impact the study by investigator~* a patient who is considered not suitable for the study by investigator~* a patient who had a history of surgery for malignant tumor within the last five years (except carcinoma in situ)~* a patient who has multisystemic wasting syndrome (such as tuberculosis, Diabetes, Thyroid disorders, tumor, etc.)~* a patient who has taken cytotoxic drugs (such as immunosuppressants, corticosteroid, cytotoxic chemotherapy, anticoagulants, etc.) during long-term

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Low dose group (Type: None): Group1. Low dose group
- High dose group (Type: None): Group2. High dose group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pancreaticoduodenectomy With or Without Braun Enteroenterostomy: Comparison of Postoperative Pancreatic Fistula and Delayed Gastric Emptying

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing pancreaticoduodenectomy surgery at Johns Hopkins Hospital~Exclusion Criteria:~* Pregnant women~* Patients under the age of 18~* adults lacking ability to consent,~* patients scheduled for laparoscopic whipple surgery~* non-english-speakers, and~* prisoners

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Braun arm (Type: ACTIVE_COMPARATOR): patients received Braun enteroenterostomy
- Non Braun Arm (Type: ACTIVE_COMPARATOR): Patients do not receive a Braun enteroenterostomy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Rosiglitazone and Insulin Resistance in Renally Impaired Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* CKD stage 4~* BMI ≤ 30~* Fasting glucose \< 7 mmol/l~Exclusion Criteria:~Exclusion of patients will take place in case of:~* A diagnosis of diabetes mellitus for which the patient uses insulin~* Significant co-morbidities which, according to the treating nephrologists, makes it unlikely that the patient will be able to complete the foreseen study period~* Significant cardiovascular co-morbidities which are likely to interfere with the objectives of the study (morbid obesity, family history of dyslipidemia, etc.); at the discretion of the treating nephrologists or the principal investigator~* Allergy for PPAR's~* Cardiac disease with marked limitation of functional capacity (New York Heart Association III or IV clinical status)~* Use of immunosuppressant agents~* History of renal transplant~* Hepatic insufficiency (defined as transaminase concentrations above \> 2.5 times the upper limit of normal for the laboratories)~* A history of alcohol abuse or excessive alcohol use defined as more than 21 consumptions per week~* For female patients: pregnancy, the intention to become pregnant within the study period, or lactating patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Antineoplaston Therapy in Treating Children With Rhabdoid Tumor of the Central Nervous System

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed Rhabdoid tumor of the central nervous system that is unlikely to respond to existing therapy and for which no curative therapy exists~* Measurable tumor by MRI scan performed within two weeks prior to study entry~* Tumor must be at least 5 mm~PATIENT CHARACTERISTICS:~Age:~* 6 months to 17 years~Performance status:~* Karnofsky 60-100%~Life expectancy:~* At least 2 months~Hematopoietic:~* WBC at least 2000/mm\^3~* Platelet count greater than 50,000/mm\^3~Hepatic:~* Bilirubin no greater than 2.5 mg/dL~* SGOT and SGPT no greater than 5 times upper limit of normal~* No hepatic failure~Renal:~* Creatinine no greater than 2.5 mg/dL~* No history of renal conditions that contraindicate high dosages of sodium~Cardiovascular:~* No uncontrolled hypertension~* No severe heart disease~* No history of congestive heart failure~* No history of other cardiovascular conditions that contraindicate high dosages of sodium~Pulmonary:~* No severe lung disease~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for 4 weeks after study participation~* No serious active infections or fever~* No other serious concomitant disease~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 4 weeks since prior immunotherapy and recovered~* No concurrent immunomodulating agents~Chemotherapy:~* At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered~* No concurrent antineoplastic agents~Endocrine therapy:~* Concurrent corticosteroids for cerebral edema allowed (must be on a stable dose for at least 1 week before study entry)~Radiotherapy:~* At least 8 weeks since prior radiotherapy and recovered~Surgery:~* Not specified~Other:~* No prior antineoplaston treatment

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Antineoplaston therapy (Type: EXPERIMENTAL): Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Dosimetry After rhTSH or Withdrawal of Thyroid Hormone in Metastatic or Locally Advanced Thyroid Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with thyroid cancer and known measurable (\>1cm) distant metastases demonstrating radioiodine uptake on a previous whole body scan~2. Patients planned for a therapeutic activity of 131I after thyroid hormone withdrawal~3. Age \>18 years~4. Previous treatment with radioiodine more than 6 months before inclusion.~5. Serum TSH level \<0.5 mU/L~6. Normal renal function with a creatinine clearance estimation using the Cockcroft-Gault formula \> 60 ml/ml~7. Effective means of contraception for female patient, at risk of pregnancy~8. Written informed consent~Exclusion Criteria:~1. Patients whose majority of tumoral lesions disclose FDG uptake without radioactive iodine uptake~2. Iodine excess (\< 50 μg/dl)~3. Large or diffuse bone or brain metastases~4. Patients with multiple small tumor foci less than 1 cm in diameter, such as miliary spread to the lungs~5. Patients already included in a therapeutic trial with an experimental medicine~6. Pregnancy and breast feeding patients~7. Subject with any kind of disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures~8. Treatment with antivitamin k

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TSH stimulation (Type: OTHER): rh TSH stimulation followed by thyroid hormon withdrawal

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues